- Home
- STX vs AZN Comparison
STX vs AZN Comparison
Compare STX & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STX | AZN |
|---|---|---|
| Founded | 1978 | 1992 |
| Country | Singapore | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2B | 316.4B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | STX | AZN |
|---|---|---|
| Price | $853.50 | $185.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 1 |
| Target Price | ★ $604.14 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | 0.46% | ★ 1.73% |
| EPS Growth | ★ 328.48 | N/A |
| EPS | ★ 8.29 | N/A |
| Revenue | ★ $7,384,000,000.00 | N/A |
| Revenue This Year | $27.73 | $10.34 |
| Revenue Next Year | $25.06 | $6.43 |
| P/E Ratio | $111.85 | ★ $31.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $124.63 | $68.62 |
| 52 Week High | $966.80 | $212.71 |
Technical Indicators
Market Signals| Indicator | STX | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 58.33 | 49.81 |
| Support Level | $695.14 | $180.98 |
| Resistance Level | N/A | $191.50 |
| Average True Range (ATR) | 48.64 | 3.00 |
| MACD | -3.37 | -0.05 |
| Stochastic Oscillator | 57.11 | 61.27 |
Price Performance
Historical ComparisonAbout STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.